Myocardial Infarction
Conditions
Brief summary
Obtaining data on efficacy (e.g. complete ST-segment resolution) depending on the time of treatment initiation and safety of prehospital and early hospital thrombolysis with Metalyse® in a real life setting outside clinical trials.
Interventions
DRUGMetalyse weight-adjusted
Sponsors
Boehringer Ingelheim
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male and female patient with suspected myocardial infarction, e.g. during transportation to the hospital by ambulance. No patient younger than 18 years. * Possibility of obtaining relevant information concerning indication or contraindication of thrombolysis in each patient * Typical chest pain with a duration of more than 30 minutes * Definite infarction signs in a 12-lead-ECG with ST-elevation \> 0.1 millivolt (mV) in \> 2 leads or recent left bundle branch block with typical clinical signs * Symptom onset \<= 6 hours
Exclusion criteria
* Patients older than 75 years (exception: patients appear much younger) * Low body weight * No persons under 18 * contraindications according to summary of product characteristics (SPC) for Metalyse
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Complete ST-segment resolution | up to 30 days | — |
| Pain relief | 90 min, 120 min, up to 30 days after treatment initiation | yes/no question |
| Change in creatine kinase (CK) | up to 24 hours | — |
| Change in creatine kinase-MB (CK-MB) | up to 24 hours | — |
| Change in troponin | up to 24 hours | — |
Outcome results
None listed